Silencing sexually transmitted infections: Topical siRNA-based interventions for the prevention of HIV and HSV

Infectious Diseases in Obstetrics and Gynecology

Volumn 2014, Issue , 2014, Pages

  Wheeler, Lee Adam ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL; GENETICS; GENITAL HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; HERPES GENITALIS; HIV INFECTIONS; HUMANS; RNA, SMALL INTERFERING;

EID: 84893749064     PISSN: 10647449     EISSN: 10980997     Source Type: Journal    
DOI: 10.1155/2014/125087     Document Type: Review

References (164)

1. Whitley R. J., Field's Virology 2001 Philadelphia, Pa, USA Lippincott Williams & Wilkins
2. Centers for Disease Control and Prevention, Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years-United States, 2005-2008. Morbidity and Mortality Weekly Report 2010 59 456 459
3. Weiss H., Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004 11 supplement 1 24A 35A 2-s2.0-1942531336 (Pubitemid 38529332)
4. Corey L., Wald A., Celum C. L., Quinn T. C., The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes 2004 35 5 435 445 2-s2.0-1842615043 10.1097/00126334-200404150-00001 (Pubitemid 38420652)
5. Koelle D. M., Wald A., Herpes simplex virus: the importance of asymptomatic shedding. Journal of Antimicrobial Chemotherapy 2000 45 supplement 3 1 8 2-s2.0-0034087351 (Pubitemid 30195568)
6. Corey L., Wald A., Patel R., Sacks S. L., Tyring S. K., Warren T., Douglas J. M. Jr., Paavonen J., Morrow R. A., Beutner K. R., Stratchounsky L. S., Mertz G., Keene O. N., Watson H. A., Tait D., Vargas-Cortes M., Once-daily valacyclovir to reduce the risk of transmission of genital herpes. The New England Journal of Medicine 2004 350 1 11 20 2-s2.0-9144260048 10.1056/NEJMoa035144 (Pubitemid 38032179)
7. Stanberry L. R., Spruance S. L., Cunningham A. L., Bernstein D. I., Mindel A., Sacks S., Tyring S., Aoki F. Y., Slaoui M., Denis M., Vandepapeliere P., Dubin G., Glycoprotein-D-adjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 2002 347 21 1652 1661 2-s2.0-0037153024 10.1056/NEJMoa011915 (Pubitemid 35340783)
8. Gupta R., Wald A., Krantz E., Selke S., Warren T., Vargas-Cortes M., Miller G., Corey L., Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. Journal of Infectious Diseases 2004 190 8 1374 1381 2-s2.0-4944256614 10.1086/424519 (Pubitemid 39332176)
9. Mertz G. J., Schmidt O., Jourden J. L., Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sexually Transmitted Diseases 1985 12 1 33 39 2-s2.0-0021911551 (Pubitemid 15143207)
10. Wald A., Carrell D., Remington M., Kexel E., Zeh J., Corey L., Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clinical Infectious Diseases 2002 34 7 944 948 2-s2.0-0036532218 10.1086/339325 (Pubitemid 34229763)
11. Bonnar P. E., Suppressive valacyclovir therapy to reduce genital herpes transmission: good public health policy? McGill Journal of Medicine 2009 12 39 46
12. Casper C., Wald A., Condom use and the prevention of genital herpes acquisition. Herpes 2002 9 1 10 14 2-s2.0-0036550343 (Pubitemid 37489856)
13. Wald A., Langenberg A. G. M., Link K., Izu A. E., Ashley R., Warren T., Tyring S., Douglas J. M. Jr., Corey L., Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. Journal of the American Medical Association 2001 285 24 3100 3106 2-s2.0-0035958293 (Pubitemid 32578207)
14. Serwadda D., Gray R. H., Sewankambo N. K., Wabwire-Mangen F., Chen M. Z., Quinn T. C., Lutalo T., Kiwanuka N., Kigozi G., Nalugoda F., Meehan M. P., Morrow R. A., Wawer M. J., Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. Journal of Infectious Diseases 2003 188 10 1492 1497 2-s2.0-10744228287 10.1086/379333 (Pubitemid 37523934)
15. Wald A., Link K., Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. Journal of Infectious Diseases 2002 185 1 45 52 2-s2.0-0036137322 10.1086/338231 (Pubitemid 34043015)
16. Freeman E. E., Weiss H. A., Glynn J. R., Cross P. L., Whitworth J. A., Hayes R. J., Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006 20 1 73 83 2-s2.0-29144444035 (Pubitemid 41818117)
17. UNAIDS, Report on the Global HIV/AIDS Epidemic 2008: Executive Summary 2008 Geneva, Switzerland UNAIDS
18. Hirsch M. S., Kaplan J. C., Prospects of therapy for infections with human T-lymphotropic virus type III. Annals of Internal Medicine 1985 103 5 750 755 2-s2.0-0022406436 (Pubitemid 16218399)
19. Beardsley T., AIDS progress. Synthetic vaccine only a distant prospect. Nature 1985 314 6013 659 2-s2.0-0022432061
20. Sarma P. S., Cremer K. J., Gruber J., Acquired immunodeficiency syndrome: progress and prospects for vaccine development. Journal of the National Cancer Institute 1988 80 15 1193 1197 2-s2.0-0023780758
21. Koff W. C., Hoth D. F., Development and testing of AIDS vaccines. Science 1988 241 4864 426 432 2-s2.0-0023731245
22. Virgin H. W., Walker B. D., Immunology and the elusive AIDS vaccine. Nature 2010 464 7286 224 231 2-s2.0-77949384495 10.1038/nature08898
23. Walker B. D., Burton D. R., Toward an AIDS vaccine. Science 2008 320 5877 760 764 2-s2.0-44049108744 10.1126/science.1152622 (Pubitemid 351929619)
24. Lagakos S. W., Gable A. R., Challenges to HIV prevention-seeking effective measures in the absence of a vaccine. The New England Journal of Medicine 2008 358 15 1543 1545 2-s2.0-42049084625 10.1056/NEJMp0802028 (Pubitemid 351519815)
25. Murphy E. L., Collier A. C., Kalish L. A., Assmann S. F., Para M. F., Flanigan T. P., Kumar P. N., Mintz L., Wallach F. R., Nemo G. J., Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Annals of Internal Medicine 2001 135 1 17 26 2-s2.0-0035800026 (Pubitemid 32619279)
26. Simon V., Ho D. D., HIV-1 dynamics in vivo: implications for therapy. Nature reviews. Microbiology 2003 1 3 181 190 2-s2.0-1842613542
27. Hogg R. S., Heath K. V., Yip B., Craib K. J. P., O'Shaughnessy M. V., Schechter M. T., Montaner J. S. G., Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Journal of the American Medical Association 1998 279 6 450 454 2-s2.0-0032507027 10.1001/jama.279.6.450 (Pubitemid 28082255)
28. Palella F. J. Jr., Delaney K. M., Moorman A. C., Loveless M. O., Fuhrer J., Satten G. A., Aschman D. J., Holmberg S. D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 1998 338 13 853 860 2-s2.0-2642709177 10.1056/NEJM199803263381301 (Pubitemid 28135961)
29. Watson D. C., Farley J. J., Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatric Infectious Disease Journal 1999 18 8 682 689 2-s2.0-0032775622 10.1097/00006454-199908000-00006 (Pubitemid 29382462)
30. de Martino M., Tovo P.-A., Balducci M., Galli L., Gabiano C., Rezza G., Pezzotti P., Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Journal of the American Medical Association 2000 284 2 190 197 2-s2.0-0034641328 (Pubitemid 30460862)
31. Chun T.-W., Carruth L., Finzi D., Shen X., DiGiuseppe J. A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T. C., Kuo Y.-H., Brookmeyer R., Zeiger M. A., Barditch-Crovo P., Siliciano R. F., Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997 387 6629 183 188 2-s2.0-0030913366 10.1038/387183a0 (Pubitemid 27209433)
32. Giacomet V., Albano F., Starace F., De Franciscis A., Giaquinto C., Castelli Gattinara G., Bruzzese E., Gabiano C., Galli L., Viganò A., Caselli D., Guarino A., Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study. Acta Paediatrica 2003 92 12 1398 1402 2-s2.0-9144272216 10.1080/08035250310006737 (Pubitemid 38114487)
33. Carrieri M. P., Raffi F., Lewden C., Sobel A., Michelet C., Cailleton V., Chêne G., Leport C., Moatti J.-P., Spire B., Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antiviral Therapy 2003 8 6 585 594 2-s2.0-9144232263 (Pubitemid 38057104)
34. Paterson D. L., Swindells S., Mohr J., Brester M., Vergis E. N., Squier C., Wagener M. M., Singh N., Hudson B., Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000 133 1 21 30 2-s2.0-0034604276 (Pubitemid 30432540)
35. Epping-Jordan J. A., Bengoa R., Kawar R., Sabaté E., The challenge of chronic conditions: WHO responds. British Medical Journal 2001 323 7319 947 948 2-s2.0-0035960277 (Pubitemid 33016039)
36. Wood E., Hogg R. S., Yip B., Harrigan P. R., O'Shaughnessy M. V., Montaner J. S. G., Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Annals of Internal Medicine 2003 139 10 810 816 2-s2.0-0346170054
37. Lanièce I., Ciss M., Desclaux A., Diop K., Mbodj F., Ndiaye B., Sylla O., Delaporte E., Ndoye I., Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003 17 3 S103 S108 2-s2.0-0041530202 10.1097/00002030-200317004-00014 (Pubitemid 36951676)
38. Weiss L., French T., Finkelstein R., Waters M., Mukherjee R., Agins B., HIV-related knowledge and adherence to HAART. AIDS Care 2003 15 5 673 679 2-s2.0-0141592341 10.1080/09540120310001595159 (Pubitemid 37193856)
39. Murphy D. A., Sarr M., Durako S. J., Moscicki A.-B., Wilson C. M., Muenz L. R., Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Archives of Pediatrics and Adolescent Medicine 2003 157 3 249 255 2-s2.0-0037345510 (Pubitemid 36343379)
40. Peters B. S., Conway K., Therapy for HIV: past, present, and future. Advances in Dental Research 2011 23 1 23 27 2-s2.0-79954608204 10.1177/0022034511399082
41. Krüsi A., Wood E., Montaner J., Kerr T., Social and structural determinants of HAART access and adherence among injection drug users. International Journal of Drug Policy 2010 21 1 4 9 2-s2.0-71149086499 10.1016/j.drugpo.2009.08.003
42. Orsi F., D'Almeida C., Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries. Current Opinion in HIV and AIDS 2010 5 3 237 241 2-s2.0-77951084973 10.1097/COH.0b013e32833860ba
43. Simon V., Vanderhoeven J., Hurley A., Ramratnam B., Louie M., Dawson K., Parkin N., Boden D., Markowitz M., Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002 16 11 1511 1519 2-s2.0-0037178323 10.1097/00002030-200207260-00008 (Pubitemid 34804216)
44. Finzi D., Hermankova M., Pierson T., Carruth L. M., Buck C., Chaisson R. E., Quinn T. C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D. D., Richman D. D., Siliciano R. F., Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997 278 5341 1295 1300 2-s2.0-14444273439 10.1126/science.278.5341.1295 (Pubitemid 27495742)
45. Zhang L., Ramratnam B., Tenner-Racz K., He Y., Vesanen M., Lewin S., Talal A., Racz P., Perelson A. S., Korber B. T., Markowitz M., Ho D. D., Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. The New England Journal of Medicine 1999 340 21 1605 1613 2-s2.0-0033609373 10.1056/NEJM199905273402101 (Pubitemid 29249429)
46. Turriziani O., Andreoni M., Antonelli G., Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clinical Microbiology and Infection 2010 16 10 1518 1524 2-s2.0-77957063611 10.1111/j.1469-0691.2010.03329.x
47. Ho D. D., Zhang L., HIV-1 rebound after anti-retroviral therapy. Nature Medicine 2000 6 7 736 737 2-s2.0-0033930509 10.1038/77447 (Pubitemid 30469408)
48. Ramratnam B., Mittler J. E., Zhang L., Boden D., Hurley A., Fang F., Macken C. A., Perelson A. S., Markowitz M., Ho D. D., The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nature Medicine 2000 6 1 82 85 2-s2.0-0033984045 10.1038/71577 (Pubitemid 30048531)
49. Hladik F., Doncel G. F., Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. Antiviral Research 2010 88 supplement 1 S3 S9 2-s2.0-78649439228 10.1016/j.antiviral.2010.09.011
50. Padian N. S., Buvé A., Balkus J., Serwadda D., Cates W. Jr., Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. The Lancet 2008 372 9638 585 599 2-s2.0-49349112505 10.1016/S0140-6736(08)60885-5
51. Paxton L. A., Hope T., Jaffe H. W., Pre-exposure prophylaxis for HIV infection: what if it works? The Lancet 2007 370 9581 89 93 2-s2.0-34447133509 10.1016/S0140-6736(07)61053-8 (Pubitemid 47033881)
52. Underhill K., Operario D., Mimiaga M. J., Skeer M. R., Mayer K. H., Implementation science of pre-exposure prophylaxis: preparing for public Use. Current HIV/AIDS Reports 2010 7 4 210 219 2-s2.0-77958103231 10.1007/s11904-010-0062-4
53. Sethi A. K., Celentano D. D., Gange S. J., Moore R. D., Gallant J. E., Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clinical Infectious Diseases 2003 37 8 1112 1118 2-s2.0-0142218458 10.1086/378301 (Pubitemid 37323668)
54. UNAIDS, World AIDS day report 2011. World AIDS Day Report 2011 Geneva, Switzerland UNAIDS
55. McElrath M. J., de Rosa S. C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O. D., Carter D. K., Hural J., Akondy R., Buchbinder S. P., Robertson M. N., Mehrotra D. V., Self S. G., Corey L., Shiver J. W., Casimiro D. R., HIV-1 vaccine-induced immunity in the test-of-concept step study: a case-cohort analysis. The Lancet 2008 372 9653 1894 1905 2-s2.0-56649114351 10.1016/S0140-6736(08)61592-5
56. Buchbinder S. P., Mehrotra D. V., Duerr A., Fitzgerald D. W., Mogg R., Li D., Gilbert P. B., Lama J. R., Marmor M., del Rio C., McElrath M. J., Casimiro D. R., Gottesdiener K. M., Chodakewitz J. A., Corey L., Robertson M. N., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. The Lancet 2008 372 9653 1881 1893 2-s2.0-56649105122 10.1016/S0140-6736(08)61591-3
57. Cohen J., Beyond thailand: making sense of a qualified AIDS vaccine 'success'. Science 2009 326 5953 652 653 2-s2.0-70350576235 10.1126/science.326- 652
58. Karasavvas N., Billings E., Rao M., Williams C., Zolla-Pazner S., Bailer R. T., Koup R. A., Madnote S., Arworn D., Shen X., The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Research and Human Retroviruses 2012 28 1444 1457
59. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., Jiwariyavej V., Dulyachai W., Pengsaa K., Wartel T. A., Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet 2012 380 1559 1567
60. Dudek T., Knipe D. M., Replication-defective viruses as vaccines and vaccine vectors. Virology 2006 344 1 230 239 2-s2.0-29144487803 10.1016/j.virol.2005.09.020 (Pubitemid 41814465)
61. Hoshino Y., Dalai S. K., Wang K., Pesnicak L., Lau T. Y., Knipe D. M., Cohen J. I., Straus S. E., Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 2005 79 410 418 (Pubitemid 39648394)
62. Bryan J. T., Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007 25 16 3001 3006 2-s2.0-33947586116 10.1016/j.vaccine.2007.01.013 (Pubitemid 46482731)
63. Zimmerman R. K., HPV vaccine and its recommendations, 2007. Journal of Family Practice 2007 56 2 S1 S5 2-s2.0-33847119771 (Pubitemid 46281116)
64. Joura E. A., Leodolter S., Hernandez-Avila M., Wheeler C. M., Perez G., Koutsky L. A., Garland S. M., Harper D. M., Tang G. W., Ferris D. G., Steben M., Jones R. W., Bryan J., Taddeo F. J., Bautista O. M., Esser M. T., Sings H. L., Nelson M., Boslego J. W., Sattler C., Barr E., Paavonen J., Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. The Lancet 2007 369 9574 1693 1702 2-s2.0-34249047002 10.1016/S0140-6736(07)60777-6 (Pubitemid 46783792)
65. Garland S. M., Hernandez-Avila M., Wheeler C. M., Perez G., Harper D. M., Leodolter S., Tang G. W. K., Ferris D. G., Steben M., Bryan J., Taddeo F. J., Railkar R., Esser M. T., Sings H. L., Nelson M., Boslego J., Sattler C., Barr E., Koutsky L. A., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New England Journal of Medicine 2007 356 19 1928 1943 2-s2.0-34248365967 10.1056/NEJMoa061760 (Pubitemid 46740303)
66. Minces L. R., McGowan I., Advances in the development of microbicides for the prevention of HIV infection. Current Infectious Disease Reports 2010 12 1 56 62 2-s2.0-77249145280 10.1007/s11908-009-0076-5
67. Lange J. M., Karam M., Piot P., Boost for vaginal microbicides against HIV. The Lancet 1993 342 8883 1356 2-s2.0-0027925132
68. Nikolic D. S., Garcia E., Piguet V., Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections. Expert Review of Anti-Infective Therapy 2007 5 1 77 88 2-s2.0-33947730261 10.1586/14787210.5.1.77 (Pubitemid 46605100)
69. Bourinbaiar A. S., Fruhstorfer E. C., The efficacy of nonoxynol-9 from an in vitro point of view. AIDS 1996 10 5 558 559 2-s2.0-0029933108 (Pubitemid 26138671)
70. Malkovsky M., Newell A., Dalgleish A. G., Inactivation of HIV by nonoxynol-9. The Lancet 1988 1 8586 645 2-s2.0-0023841032 (Pubitemid 18083248)
71. Herold B. C., Kirkpatrick R., Marcellino D., Travelstead A., Pilipenko V., Krasa H., Bremer J., Dong L. J., Cooper M. D., Bile salts: natural detergents for the prevention of sexually transmitted diseases. Antimicrobial Agents and Chemotherapy 1999 43 4 745 751 2-s2.0-0032917883 (Pubitemid 29165734)
72. Stafford M. K., Ward H., Flanagan A., Rosenstein I. J., Taylor-Robinson D., Smith J. R., Weber J., Kitchen V. S., Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998 17 4 327 331 2-s2.0-0031891991
73. Roddy R. E., Zekeng L., Ryan K. A., Tamoufé U., Weir S. S., Wong E. L., A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. The New England Journal of Medicine 1998 339 8 504 510 2-s2.0-0032552228 10.1056/NEJM199808203390803 (Pubitemid 28384883)
74. van Damme L., Ramjee G., Alary M., Vuylsteke B., Chandeying V., Rees H., Sirivongrangson P., Mukenge-Tshibaka L., Ettiègne-Traoré V., Uaheowitchai C., Abdool Karim S. S., Mâsse B., Perriëns J., Laga M., Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. The Lancet 2002 360 9338 971 977 2-s2.0-0037190597 10.1016/S0140-6736(02)11079-8 (Pubitemid 35284107)
75. Hillier S. L., Moench T., Shattock R., Black R., Reichelderfer P., Veronese F., In vitro and in vivo: the story of nonoxynol 9. Journal of Acquired Immune Deficiency Syndromes 2005 39 1 1 8 2-s2.0-18144365830 10.1097/01.qai.0000159671.25950.74 (Pubitemid 40617012)
76. Mayer K. H., Peipert J., Fleming T., Fullem A., Moench T., Cu-Uvin S., Bentley M., Chesney M., Rosenberg Z., Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clinical Infectious Diseases 2001 32 3 476 482 2-s2.0-0035112881 10.1086/318496 (Pubitemid 32173636)
77. van Damme L., Govinden R., Mirembe F. M., Guédou F., Solomon S., Becker M. L., Pradeep B. S., Krishnan A. K., Alary M., Pande B., Ramjee G., Deese J., Crucitti T., Taylor D., Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. The New England Journal of Medicine 2008 359 5 463 472 2-s2.0-48249154985 10.1056/NEJMoa0707957
78. Keller M. J., Tuyama A., Carlucci M. J., Herold B. C., Topical microbicides for the prevention of genital herpes infection. Journal of Antimicrobial Chemotherapy 2005 55 4 420 423 2-s2.0-17444386394 10.1093/jac/dki056 (Pubitemid 40542578)
79. McGowan I., Microbicides for HIV prevention: reality or hope? Current Opinion in Infectious Diseases 2010 23 1 26 31 2-s2.0-74249097557 10.1097/QCO.0b013e328334fe70
80. Karim Q. A., Karim S. S. A., Frohlich J. A., Grobler A. C., Baxter C., Mansoor L. E., Kharsany A. B. M., Sibeko S., Mlisana K. P., Omar Z., Gengiah T. N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010 329 5996 1168 1174 2-s2.0-77955930318 10.1126/science.1193748
81. McGowan I., Rectal microbicide development. Current Opinion in HIV and AIDS 2012 7 526 533
82. Anton P. A., Cranston R. D., Kashuba A., Hendrix C. W., Bumpus N. N., Richardson-Harman N., Elliott J., Janocko L., Khanukhova E., Dennis R., RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Research and Human Retroviruses 2012 28 1412 1421
83. Celum C., Baeten J. M., Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Current Opinion in Infectious Diseases 2012 25 1 51 57 2-s2.0-84155171087 10.1097/QCO.0b013e32834ef5ef
84. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 6836 494 498 2-s2.0-0035942736 10.1038/35078107 (Pubitemid 32494397)
85. Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C., Potent and specific genetic interference by double-stranded RNA in caenorhabditis elegans. Nature 1998 391 6669 806 811 2-s2.0-0032545933 10.1038/35888 (Pubitemid 28099681)
86. Jorgensen R., Altered gene expression in plants due to trans interactions between homologous genes. Trends in Biotechnology 1990 8 12 340 344 2-s2.0-0025134418
87. Wightman B., Ha I., Ruvkun G., Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993 75 5 855 862 2-s2.0-0027730383 10.1016/0092-8674(93)90530-4 (Pubitemid 24014543)
88. Lee R. C., Feinbaum R. L., Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993 75 5 843 854 2-s2.0-0027751663 10.1016/0092-8674(93)90529-Y (Pubitemid 24014542)
89. Novina C. D., Murray M. F., Dykxhoorn D. M., Beresford P. J., Riess J., Lee S.-K., Collman R. G., Lieberman J., Shankar P., Sharp P. A., siRNA-directed inhibition of HIV-1 infection. Nature Medicine 2002 8 681 686 (Pubitemid 34778720)
90. Lee S.-K., Dykxhoorn D. M., Kumar P., Ranjbar S., Song E., Maliszewski L. E., François-Bongarçon V., Goldfeld A., Swamy N. M., Lieberman J., Shankar P., Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood 2005 106 3 818 826 2-s2.0-23044517213 10.1182/blood-2004-10-3959 (Pubitemid 41076420)
91. Kumar P., Ban H.-S., Kim S.-S., Wu H., Pearson T., Greiner D. L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.-G., Jeong J.-H., Lee K.-Y., Kim Y.-H., Kim S. W., Peipp M., Fey G. H., Manjunath N., Shultz L. D., Lee S.-K., Shankar P., T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008 134 4 577 586 2-s2.0-49549117077 10.1016/j.cell.2008. 06.034
92. Song E., Lee S.-K., Dykxhoorn D. M., Novina C., Zhang D., Crawford K., Cerny J., Sharp P. A., Lieberman J., Manjunath N., Shankar P., Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. Journal of Virology 2003 77 13 7174 7181 2-s2.0-0037663944 10.1128/JVI.77.13.7174-7181.2003 (Pubitemid 36734486)
93. Song E., Zhu P., Lee S.-K., Chowdhury D., Kussman S., Dykxhoorn D. M., Feng Y., Palliser D., Weiner D. B., Shankar P., Marasco W. A., Lieberman J., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnology 2005 23 6 709 717 2-s2.0-23844474160 10.1038/nbt1101 (Pubitemid 41716361)
94. Bitko V., Musiyenko A., Shulyayeva O., Barik S., Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine 2005 11 1 50 55 2-s2.0-13444262170 10.1038/nm1164 (Pubitemid 40215837)
95. Palliser D., Chowdhury D., Wang Q.-Y., Lee S. J., Bronson R. T., Knipe D. M., Lieberman J., An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 2006 439 7072 89 94 2-s2.0-30144434185 10.1038/nature04263 (Pubitemid 43053634)
96. Wu Y., Navarro F., Lal A., Basar E., Pandey R. K., Manoharan M., Feng Y., Lee S. J., Lieberman J., Palliser D., Durable protection from herpes simplex virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host and Microbe 2009 5 1 84 94 2-s2.0-58249094519 10.1016/j.chom.2008.12.003
97. Peer D., Eun J. P., Morishita Y., Carman C. V., Shimaoka M., Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008 319 5863 627 630 2-s2.0-38849166053 10.1126/science.1149859 (Pubitemid 351197066)
98. Peer D., Zhu P., Carman C. V., Lieberman J., Shimaoka M., Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proceedings of the National Academy of Sciences of the United States of America 2007 104 10 4095 4100 2-s2.0-34247255870 10.1073/pnas.0608491104 (Pubitemid 47181584)
99. Song E., Lee S.-K., Wang J., Ince N., Ouyang N., Min J., Chen J., Shankar P., Lieberman J., RNA interference targeting Fas protects mice from fulminant hepatitis. Nature Medicine 2003 9 3 347 351 2-s2.0-0037348329 10.1038/nm828 (Pubitemid 36362792)
100. Hamar P., Song E., Kökeny G., Chen A., Ouyang N., Lieberman J., Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2004 101 41 14883 14888 2-s2.0-6944238701 10.1073/pnas.0406421101 (Pubitemid 39410769)
101. Dykxhoorn D. M., Chowdhury D., Lieberman J., RNA interference and cancer: endogenous pathways and therapeutic approaches. Advances in Experimental Medicine and Biology 2008 615 299 329 2-s2.0-43249091971 10.1007/978-1-4020- 6554-5-14
102. Pai S. I., Lin Y.-Y., Macaes B., Meneshian A., Hung C.-F., Wu T.-C., Prospects of RNA interference therapy for cancer. Gene Therapy 2006 13 6 464 477 2-s2.0-33645167401 10.1038/sj.gt.3302694
103. Brummelkamp T. R., Bernards R., Agami R., Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002 2 3 243 247 2-s2.0-0036726313 10.1016/S1535-6108(02)00122-8 (Pubitemid 41043979)
104. Kim D. H., Rossi J. J., RNAi mechanisms and applications. BioTechniques 2008 44 5 613 616 2-s2.0-43249103387 10.2144/000112792 (Pubitemid 351656279)
105. Wheeler L. A., Dykxhoorn D. M., RNAi as a potential new therapy for HIV infection. Future HIV Therapy 2008 2 6 567 577 2-s2.0-67149131702 10.2217/17469600.2.6.567
106. Schwarz D. S., Hutvágner G., Du T., Xu Z., Aronin N., Zamore P. D., Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003 115 2 199 208 2-s2.0-10744225153 10.1016/S0092-8674(03)00759-1 (Pubitemid 37329583)
107. Matranga C., Tomari Y., Shin C., Bartel D. P., Zamore P. D., Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005 123 4 607 620 2-s2.0-27744590896 10.1016/j.cell.2005.08.044 (Pubitemid 41608464)
108. Dykxhoorn D. M., Lieberman J., Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annual Review of Biomedical Engineering 2006 8 377 402 2-s2.0-33748201603 10.1146/annurev.bioeng.8.061505.095848 (Pubitemid 44314822)
109. Bartel D. P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004 116 2 281 297 2-s2.0-0347444723 10.1016/S0092-8674(04)00045-5 (Pubitemid 38167318)
110. Stefani G., Slack F. J., Small non-coding RNAs in animal development. Nature Reviews Molecular Cell Biology 2008 9 3 219 230 2-s2.0-39749110083 10.1038/nrm2347 (Pubitemid 351301826)
111. Wu L., Belasco J. G., Let Me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Molecular Cell 2008 29 1 1 7 2-s2.0-38148999355 10.1016/j.molcel.2007.12.010
112. de Fougerolles A., Vornlocher H.-P., Maraganore J., Lieberman J., Interfering with disease: a progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery 2007 6 6 443 453 2-s2.0-34447559636 10.1038/nrd2310 (Pubitemid 47064567)
113. Berkhout B., Ter Brake O., Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opinion on Biological Therapy 2009 9 2 161 170 2-s2.0-66149132733 10.1517/14712590802653619
114. Capodici J., Karikó K., Weissman D., Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. Journal of Immunology 2002 169 9 5196 5201 2-s2.0-0036839458 (Pubitemid 35217190)
115. Coburn G. A., Cullen B. R., Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. Journal of Virology 2002 76 18 9225 9231 2-s2.0-0036721314 10.1128/JVI.76.18.9225-9231.2002 (Pubitemid 34919881)
116. Jacque J.-M., Triques K., Stevenson M., Modulation of HIV-1 replication by RNA interference. Nature 2002 418 6896 435 438 2-s2.0-0037173610 10.1038/nature00896 (Pubitemid 34826845)
117. Lee N. S., Dohjima T., Bauer G., Li H., Li M.-J., Ehsani A., Salvaterra P., Rossi J., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nature Biotechnology 2002 20 5 500 505 2-s2.0-0036256430 10.1038/nbt0502-500 (Pubitemid 34495938)
118. Brass A. L., Dykxhoorn D. M., Benita Y., Yan N., Engelman A., Xavier R. J., Lieberman J., Elledge S. J., Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008 319 5865 921 926 2-s2.0-39349097864 10.1126/science.1152725 (Pubitemid 351263756)
119. Gao Y., Lobritz M. A., Roth J., Abreha M., Nelson K. N., Nankya I., Moore-Dudley D. M., Abraha A., Gerson S. L., Arts E. J., Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. Journal of Virology 2008 82 6 2938 2951 2-s2.0-40149086062 10.1128/JVI.02126-07 (Pubitemid 351329183)
120. Alvarez R., Elbashir S., Borland T., Toudjarska I., Hadwiger P., John M., Roehl I., Morskaya S. S., Martinello R., Kahn J., van Ranst M., Tripp R. A., DeVincenzo J. P., Pandey R., Maier M., Nechev L., Manoharan M., Kotelianski V., Meyers R., RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrobial Agents and Chemotherapy 2009 53 9 3952 3962 2-s2.0-70349147840 10.1128/AAC.00014-09
121. Zhang W., Yang H., Kong X., Mohapatra S., San Juan-Vergara H., Hellermann G., Behera S., Singam R., Lockey R. F., Mohapatra S. S., Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nature Medicine 2005 11 1 56 62 2-s2.0-13444252624 10.1038/nm1174 (Pubitemid 40215838)
122. Wheeler L. A., Vrbanac V., Trifonova R., Brehm M. A., Gilboa-Geffen A., Tanno S., Greiner D. L., Luster A. D., Tager A. M., Lieberman J., Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Molecular Therapy 2013 21 1378 1389
123. Wheeler L. A., Trifonova R., Vrbanac V., Basar E., McKernan S., Xu Z., Seung E., Deruaz M., Dudek T., Einarsson J. I., Yang L., Allen T. M., Luster A. D., Tager A. M., Dykxhoorn D. M., Lieberman J., Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. Journal of Clinical Investigation 2011 121 6 2401 2412 2-s2.0-79957905425 10.1172/JCI45876
124. Grant R. M., Hamer D., Hope T., Johnston R., Lange J., Lederman M. M., Lieberman J., Miller C. J., Moore J. P., Mosier D. E., Richman D. D., Schooley R. T., Springer M. S., Veazey R. S., Wainberg M. A., Whither or wither microbicides? Science 2008 321 5888 532 534 2-s2.0-48249121565 10.1126/science.1160355
125. Yano J., Hirabayashi K., Nakagawa S.-I., Yamaguchi T., Nogawa M., Kashimori I., Naito H., Kitagawa H., Ishiyama K., Ohgi T., Irimura T., Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clinical Cancer Research 2004 10 22 7721 7726 2-s2.0-9344224580 10.1158/1078-0432.CCR-04-1049 (Pubitemid 39557537)
126. Anderson J., Banerjea A., Planelles V., Akkina R., Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Research and Human Retroviruses 2003 19 8 699 706 2-s2.0-0041322735 10.1089/ 088922203322280928 (Pubitemid 37047095)
127. Devroe E., Silver P. A., Therapeutic potential of retroviral RNAi vectors. Expert Opinion on Biological Therapy 2004 4 3 319 327 2-s2.0-1542782936 10.1517/14712598.4.3.319 (Pubitemid 38352128)
128. Lewis D. L., Wolff J. A., Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods in
129. Lorenz C., Hadwiger P., John M., Vornlocher H.-P., Unverzagt C., Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorganic and Medicinal Chemistry Letters 2004 14 19 4975 4977 2-s2.0-4444220551 10.1016/j.bmcl.2004.07.018 (Pubitemid 39165605)
130. Minakuchi Y., Takeshita F., Kosaka N., Sasaki H., Yamamoto Y., Kouno M., Honma K., Nagahara S., Hanai K., Sano A., Kato T., Terada M., Ochiya T., Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Research 2004 32 13 e109 2-s2.0-3242733298
131. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Gelck A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R. K., Racie T., Rajeev K. S., Röhl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Kotellansky V., Limmer S., Manoharan M., Vornlocher H.-P., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 432 7014 173 178 2-s2.0-9144247189 10.1038/nature03121 (Pubitemid 39545841)
132. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A., RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Therapy 2005 12 5 461 466 2-s2.0-15444373116 10.1038/sj.gt.3302425 (Pubitemid 40394299)
133. Stull R. A., Szoka F. C. Jr., Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects. Pharmaceutical Research 1995 12 4 465 483 2-s2.0-0028943759
134. Scherer L., Rossi J. J., Weinberg M. S., Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Therapy 2007 14 14 1057 1064 2-s2.0-34447094733 10.1038/sj.gt.3302977 (Pubitemid 47029489)
135. Held D. M., Kissel J. D., Patterson J. T., Nickens D. G., Burke D. H., HIV-1 inactivation by nucleic acid aptamers. Frontiers in Bioscience 2006 11 1 89 112 2-s2.0-32844463163 (Pubitemid 43253477)
136. McNamara J. O. II, Andrechek E. R., Wang Y., Viles K. D., Rempel R. E., Gilboa E., Sullenger B. A., Giangrande P. H., Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nature Biotechnology 2006 24 8 1005 1015 2-s2.0-33747031960 10.1038/nbt1223 (Pubitemid 44215395)
137. Dassie J. P., Liu X.-Y., Thomas G. S., Whitaker R. M., Thiel K. W., Stockdale K. R., Meyerholz D. K., McCaffrey A. P., McNamara J. O., Giangrande P. H., Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotechnology 2009 27 9 839 846 2-s2.0-70249110439 10.1038/nbt.1560
138. Zhou J., Li H., Li S., Zaia J., Rossi J. J., Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Molecular Therapy 2008 16 8 1481 1489 2-s2.0-48349105059 10.1038/mt.2008.92
139. Zhou J., Swiderski P., Li H., Zhang J., Neff C. P., Akkina R., Rossi J. J., Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Research 2009 37 9 3094 3109 2-s2.0-66249129385 10.1093/nar/gkp185
140. Neff C. P., Zhou J., Remling L., Kuruvilla J., Zhang J., Li H., Smith D. D., Swiderski P., Rossi J. J., Akkina R., An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice. Science Translational Medicine 2011 3 66 2-s2.0-78751667739 10.1126/scitranslmed.3001581 66ra6
141. Brainard D. M., Seung E., Frahm N., Cariappa A., Bailey C. C., Hart W. K., Shin H.-S., Brooks S. F., Knight H. L., Eichbaum U., Yang Y.-G., Sykes M., Walker B. D., Freeman G. J., Pillai S., Westmoreland S. V., Brander C., Luster A. D., Tager A. M., Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. Journal of Virology 2009 83 14 7305 7321 2-s2.0-67650410026 10.1128/JVI.02207-08
142. Zhou J., Li H., Zhang J., Piotr S., Rossi J., Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. Journal of Visualized Experiments 2011 52 2-s2.0-80355135153 10.3791/2954 e2954
143. OPKO Health, OPKO Health announces update on Phase III clinical trial of bevasiranib. Press release
144. Robbins M., Judge A., MacLachlan I., SiRNA and innate immunity. Oligonucleotides 2009 19 2 89 102 2-s2.0-66249105368 10.1089/oli.2009.0180
145. Katakowski J. A., Palliser D., SiRNA-based topical microbicides targeting sexually transmitted infections. Current Opinion in Molecular Therapeutics 2010 12 2 192 202 2-s2.0-77950826873
146. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., De Fougerolles A., Endres S., Hartmann G., Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Medicine 2005 11 3 263 270 2-s2.0-20144389695 10.1038/nm1191 (Pubitemid 40460553)
147. Judge A. D., Sood V., Shaw J. R., Fang D., McClintock K., MacLachlan I., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nature Biotechnology 2005 23 4 457 462 2-s2.0-22344454846 10.1038/nbt1081 (Pubitemid 41724921)
148. Robbins M., Judge A., Ambegia E., Choi C., Yaworski E., Palmer L., McClintock K., MacLachlan I., Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Human Gene Therapy 2008 19 10 991 999 2-s2.0-54949095836 10.1089/hum.2008.131
149. Schlee M., Hornung V., Hartmann G., siRNA and isRNA: two edges of one sword. Molecular Therapy 2006 14 4 463 470 2-s2.0-33748069824 10.1016/j.ymthe.2006.06.001 (Pubitemid 44296098)
150. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S. S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., Schmidt A., Anz D., Bscheider M., Schwerd T., Berking C., Bourquin C., Kalinke U., Kremmer E., Kato H., Akira S., Meyers R., Häcker G., Neuenhahn M., Busch D., Ruland J., Rothenfusser S., Prinz M., Hornung V., Endres S., Tüting T., Hartmann G., 5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine 2008 14 11 1256 1263 2-s2.0-55549114663 10.1038/nm.1887
151. Jackson A. L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J. M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P. S., Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006 12 7 1197 1205 2-s2.0-33745614074 10.1261/rna.30706 (Pubitemid 43990545)
152. Ui-Tei K., Naito Y., Zenno S., Nishi K., Yamato K., Takahashi F., Juni A., Saigo K., Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Research 2008 36 7 2136 2151 2-s2.0-42449091989 10.1093/nar/gkn042 (Pubitemid 351566989)
153. Laursen M. B., Pakula M. M., Gao S., Fluiter K., Mook O. R., Baas F., Langklær N., Wengel S. L., Wengel J., Kjems J., Bramsen J. B., Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo. Molecular BioSystems 2010 6 5 862 870 2-s2.0-77952329345 10.1039/b918869j
154. Chiu Y.-L., Rana T. M., RNAi in human cells: basic structural and functional features of small interfering RNA. Molecular Cell 2002 10 3 549 561 2-s2.0-0036752785 10.1016/S1097-2765(02)00652-4 (Pubitemid 35284173)
155. Kleinman M. E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J. Z., Albuquerque R. J. C., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Karikó K., Ambati B. K., Wilgus T. A., DiPietro L. A., Sakurai E., Zhang K., Smith J. R., Taylor E. W., Ambati J., Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008 452 7187 591 597 2-s2.0-41649115210 10.1038/nature06765 (Pubitemid 351483358)
156. Zimmermann T. S., Lee A. C. H., Akinc A., Bramlage B., Bumcrot D., Fedoruk M. N., Harborth J., Heyes J. A., Jeffs L. B., John M., Judge A. D., Lam K., McClintock K., Nechev L. V., Palmer L. R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A. J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.-P., MacLachlan I., RNAi-mediated gene silencing in non-human primates. Nature 2006 441 1 111 114 2-s2.0-33646185371 10.1038/nature04688
157. Khan A. A., Betel D., Miller M. L., Sander C., Leslie C. S., Marks D. S., Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnology 2009 27 6 549 555 2-s2.0-67149115119 10.1038/nbt.1543
158. Grimm D., Streetz K. L., Jopling C. L., Storm T. A., Pandey K., Davis C. R., Marion P., Salazar F., Kay M. A., Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006 441 7092 537 541 2-s2.0-33745299723 10.1038/nature04791 (Pubitemid 44050158)
159. John M., Constien R., Akinc A., Goldberg M., Moon Y.-A., Spranger M., Hadwiger P., Soutschek J., Vornlocher H.-P., Manoharan M., Stoffel M., Langer R., Anderson D. G., Horton J. D., Koteliansky V., Bumcrot D., Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007 449 7163 745 747 2-s2.0-35148845281 10.1038/nature06179 (Pubitemid 47552094)
160. McBride J. L., Boudreau R. L., Harper S. Q., Staber P. D., Monteys A. M., Martins I., Gilmore B. L., Burstein H., Peluso R. W., Polisky B., Carter B. J., Davidson B. L., Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proceedings of the National Academy of Sciences of the United States of America 2008 105 15 5868 5873 2-s2.0-44449121785 10.1073/pnas.0801775105 (Pubitemid 351758464)
161. Judge A. D., Bola G., Lee A. C. H., MacLachlan I., Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Molecular Therapy 2006 13 3 494 505 2-s2.0-32944454941 10.1016/j.ymthe.2005.11. 002 (Pubitemid 43257617)
162. Castanotto D., Sakurai K., Lingeman R., Li H., Shively L., Aagaard L., Soifer H., Gatignol A., Riggs A., Rossi J. J., Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Research 2007 35 15 5154 5164 2-s2.0-34548548614 10.1093/nar/gkm543 (Pubitemid 47394199)
163. de Fougerolles A. R., Delivery vehicles for small interfering RNA in vivo. Human Gene Therapy 2008 19 2 125 132 2-s2.0-39549117983 10.1089/hum.2008.928 (Pubitemid 351278372)
164. Davidson B. L., McCray P. B. Jr., Current prospects for RNA interference-based therapies. Nature Reviews Genetics 2011 12 5 329 340 2-s2.0-79954580272 10.1038/nrg2968